1. Home
  2. XWEL vs SNGX Comparison

XWEL vs SNGX Comparison

Compare XWEL & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XWEL

XWELL Inc.

HOLD

Current Price

$0.72

Market Cap

9.2M

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

SELL

Current Price

$0.38

Market Cap

7.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
XWEL
SNGX
Founded
2006
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
7.6M
IPO Year
2010
2006

Fundamental Metrics

Financial Performance
Metric
XWEL
SNGX
Price
$0.72
$0.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
44.9K
★ 123.6K
Earning Date
11-13-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.03
EPS
N/A
★ N/A
Revenue
★ $29,210,000.00
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.26
$0.32
52 Week High
$2.20
$3.39

Technical Indicators

Market Signals
Indicator
XWEL
SNGX
Relative Strength Index (RSI) 41.13 39.28
Support Level $0.57 $0.37
Resistance Level $0.96 $0.82
Average True Range (ATR) 0.08 0.02
MACD 0.00 0.02
Stochastic Oscillator 39.73 95.40

Price Performance

Historical Comparison
XWEL
SNGX

About XWEL XWELL Inc.

XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Share on Social Networks: